Aurum Ventures Invests $1.2M in Hebrew U's Yissum for Circulating DNA Test Development | GenomeWeb

NEW YORK (GenomeWeb) – The Hebrew University of Jerusalem's Yissum Research Development Company said today that it has received a $1.2 million investment from Aurum Ventures MKI to support its development of circulating cell-free DNA-based diagnostics for a variety of diseases.

The method Yissum plans to advance is based on the detection of methylation markers in circulating DNA, which can serve as biomarkers for specific disease states in the body.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.